Soft Tissue Sarcoma
Halaven Study Improves Overall Survival In Liposarcomas and Leiomyosarcomas
Full results from a phase III study showed improved median overall survival in unresectable locally advanced liposarcomas and leiomyosarcomas in patients receiving Halaven (eribulin), compared to dacarbazine.
The clinical trial, study 309, included data from 452 adults, and was published in The Lancet, which also published an editorial discussing the study results.
The study compared patients treated with eribulin mesilate (1.4 mg/msquared intravenously on days 1 and 8) and those treated with dacarbazine (850 mg/msquared, 1000 mg/msquared, or 1200 mg/msquared [dose dependent on center and clinician] intravenously on day 1). Additional endpoints included progression-free survival and quality of life.